@entity4091 in XXXX .

@entity1 @entity1033 @entity500 @entity5 @entity1252 @entity786 @entity4091 @entity1988 @entity281 @entity51 @entity14000 @entity204
OBJECTIVE: To define the clinical spectrum and @entity4091 and to determine the risk factors associated with the development of @entity4091 in @entity1 with @entity1252 ( @entity1252 ). METHODS: Retrospective matched case control study in a consecutive series of @entity1 with @entity1252 first evaluated between 1979 and 1989. @entity1 were classified as cases if their first episode of @entity4091 occurred after lupus diagnosis. @entity1252 @entity1 who never had @entity4091 were eligible as controls and were matched 2:1 to cases for age, race, sex, and survival status. Clinical features of the cases from the time of lupus diagnosis to the time of @entity4091 were compared to their respective controls over similar time periods. RESULTS: Forty eight (15%) of 321 @entity1 were classified as cases. Cases were more likely to have received @entity786 (p = 0.03), and @entity500 (p = 0.006). More cases had @entity1988 (p = 0.02), and a concurrent or previous @entity5 (p = 0.01) than their controls. Seven cases had cutaneous dissemination. Seven @entity1 had @entity14000 > 2 months and in only 2 @entity1 symptoms persisted for > 12 months' duration. Only 3 of 36 @entity1 had immunosuppressive medication discontinued at the time of diagnosis of @entity4091 , and 10 cases received @entity1033 for the @entity281 . There were no permanent @entity51 or @entity204 . CONCLUSION: Immunosuppressive therapy, specifically @entity786 and @entity500 , @entity1988 , and a concurrent or previous @entity5 may be risk factors for the development of herpes @entity281 in @entity1 with @entity1252 . Our study suggests that although @entity4091 occurs frequently in @entity1 with @entity1252 , it has a relatively benign course. Discontinuing needed immunosuppressive therapy in @entity1 with @entity1252 may be unnecessary in the setting of a @entity281 . With the current emphasis on reduction in medical costs, both by limiting inpatient admissions and eliminating unneeded medications, it is necessary to identify which @entity1 require more intensive therapy with antiviral medications and/or hospitalization and which are likely to have a benign, self-limited course without intervention.
